☆ 4.6 Editorial Material

Paving the Way Toward Meaningful Trials in Ataxias: An Ataxia Global Initiative Perspective

MOVEMENT DISORDERS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF)

Ruben P. A. van Eijk et al.

Summary: ALS patients have diverse preferences and needs, leading to the development of a new endpoint (PROOF) that focuses on patient function improvement. It provides a patient-centered analysis to refine risk-benefit assessment of new treatments for ALS.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

添加到收藏夹

Article Clinical Neurology

Real-Life Turning Movements Capture Subtle Longitudinal and Preataxic Changes in Cerebellar Ataxia

Annika Thierfelder et al.

Summary: This longitudinal study aimed to identify quantitative motor biomarkers in degenerative ataxias in real-life turning movements that are sensitive to longitudinal changes and the preataxic stage. The results showed that measures of dynamic balance during turning were able to differentiate ataxic subjects from healthy controls in real life, with high sensitivity to longitudinal differences in ataxia severity and the preataxic stage.

MOVEMENT DISORDERS (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives

Matthis Synofzik et al.

Summary: ASO therapies offer a promising disease-modifying approach for rare neurological diseases, but there is a need to focus on ultrarare or private variants to provide treatment for a larger share of patients. The emerging field of n-of-1 ASO treatment approaches requires systematic guidance and standards to allow global scaling, particularly in the European context. Genetic, regulatory, and ethical perspectives are essential for preparing and implementing n-of-1 ASO treatments to ensure both individual patient benefit and knowledge gain.

NUCLEIC ACID THERAPEUTICS (2022)

添加到收藏夹

Article Clinical Neurology

Development of SARAhome, a New Video-Based Tool for the Assessment of Ataxia at Home

Marcus Grobe-Einsler et al.

Summary: The study developed a video-based tool called SARA(home) for measuring ataxia severity at home, which was highly correlated with the conventional SARA. The feasibility of independent home recordings was demonstrated, showing a considerable degree of intraindividual variability in SARA(home) scores.

MOVEMENT DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology

Pre-ataxic Changes of Clinical Scales and Eye Movement in Machado-Joseph Disease: BIGPRO Study

Camila Maria de Oliveira et al.

Summary: This study validates biomarkers for disease progression in spinocerebellar ataxia type 3 patients before symptoms appear. Clinical scales and oculomotor neurophysiology variables were already altered in pre-ataxic patients and worsened with time, making them good candidates to measure preclinical changes.

MOVEMENT DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology

Natural History, Phenotypic Spectrum, and Discriminative Features of Multisystemic RFC1 Disease

Andreas Traschutz et al.

Summary: The study found that RFC1 disease is common across different populations, with CANVAS and ACC as highly diagnostic features, but the phenotype is variable and overlapping, spanning a spectrum of multisystem diseases. Treatment trials require a large number of patients to detect reduced progression.

NEUROLOGY (2021)

添加到收藏夹

Review Clinical Neurology

Gene Therapy for Polyglutamine Spinocerebellar Ataxias: Advances, Challenges, and Perspectives

Yaimee Vazquez-Mojena et al.

Summary: Polyglutamine spinocerebellar ataxias are a group of autosomal dominant disorders caused by repeat expansions in single genes. While there is currently no curative treatment available, gene therapy strategies like RNA interference and antisense oligonucleotide therapy have shown promise in cellular and animal models. Gene editing strategies such as CRISPR/Cas9 have also been introduced to a limited extent, but face technological and ethical challenges in their potential use in future clinical trials.

MOVEMENT DISORDERS (2021)

添加到收藏夹

Article Neurosciences

A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases

Jonathan M. Fischell et al.

Summary: Despite significant progress in gene therapy technologies, there are currently no approved gene therapies specifically for brain diseases, mainly due to the presence of the blood-brain barrier (BBB). Various approaches, including direct intracerebral injection of vectors, have limitations. Innovative methods are needed to enhance the efficiency of gene delivery to the brain.

FRONTIERS IN NEUROSCIENCE (2021)

添加到收藏夹

Article Clinical Neurology

Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study

Kathrin Reetz et al.

Summary: The EFACTS study aimed to assess progression characteristics and identify patient groups with differential progression rates in Friedreich's ataxia using 4-year longitudinal data. Results showed significant differences in disease progression based on age of onset and ambulatory abilities.

LANCET NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Regional Brain and Spinal Cord Volume Loss in Spinocerebellar Ataxia Type 3

Jennifer Faber et al.

Summary: The study aimed to quantify regional brain volumes and cervical spinal cord areas in spinocerebellar ataxia type 3 patients using MRI, revealing that tissue loss in the brain and spinal cord starts before ataxia onset in early-stage patients. Pontine volume is identified as a potential imaging biomarker candidate for intervention trials aiming to slow the progression of the disease.

MOVEMENT DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology

Gait Variability in Spinocerebellar Ataxia Assessed Using Wearable Inertial Sensors

Vrutangkumar V. Shah et al.

Summary: This study identified gait variability as the most discriminative feature of SCA, with measures like toe-out angle and double-support time variability showing high sensitivity and specificity. These variability measures were also correlated with disease severity, suggesting their potential utility as clinical trial outcome measures for both manifest and prodromal SCAs.

MOVEMENT DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology

Development and Validation of a Patient-Reported Outcome Measure of Ataxia

Jeremy D. Schmahmann et al.

Summary: The study developed a Patient-Reported Outcome Measure of Ataxia through online surveys completed by ataxia patients, scored on a 0-4 Likert scale. The measurement showed high internal consistency and reliability, and was sensitive to ataxia severity. It was significantly associated with measures of ataxia, quality of life, and mental health.

MOVEMENT DISORDERS (2021)

添加到收藏夹

Article Neurosciences

Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia

Giulia Coarelli et al.

Summary: This study found that in autosomal dominant spinocerebellar ataxias (SCAs), NfL levels can better predict clinical manifestations and brain changes. Additionally, NfL levels may help refine inclusion criteria for carriers in clinical trials.

NEUROBIOLOGY OF DISEASE (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice

Carlo Wilke et al.

EMBO MOLECULAR MEDICINE (2020)

添加到收藏夹

Article Clinical Neurology

Real-life gait assessment in degenerative cerebellar ataxia Toward ecologically valid biomarkers

Winfried Ilg et al.

NEUROLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Timothy Miller et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Development of a knowledge translation platform for ataxia: Impact on readers and volunteer contributors

Celeste Elisabeth Suart et al.

PLOS ONE (2020)

添加到收藏夹

Review Neurosciences

Autosomal Recessive Cerebellar Ataxias: Paving the Way toward Targeted Molecular Therapies

Matthis Synofzik et al.

NEURON (2019)

添加到收藏夹

Article Clinical Neurology

Loss of paraplegin drives spasticity rather than ataxia in a cohort of 241 patients with SPG7

Giulia Coarelli et al.

NEUROLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Targeting Huntingtin Expression in Patients with Huntington's Disease

Sarah J. Tabrizi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Spinocerebellar ataxia

Thomas Klockgether et al.

NATURE REVIEWS DISEASE PRIMERS (2019)

添加到收藏夹

Article Neurosciences

The Classification of Autosomal Recessive Cerebellar Ataxias: a Consensus Statement from the Society for Research on the Cerebellum and Ataxias Task Force

Marie Beaudin et al.

CEREBELLUM (2019)

添加到收藏夹

Article Clinical Neurology

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study

Darryl C. De Vivo et al.

NEUROMUSCULAR DISORDERS (2019)

添加到收藏夹

Proceedings Paper Engineering, Biomedical

Quantitative Assessment of Cerebella Ataxia, through Automated Limb-Coordination tests

Ragil Krishna et al.

2019 41ST ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC) (2019)

添加到收藏夹

Article Clinical Neurology

Neurochemical abnormalities in premanifest and early spinocerebellar ataxias

James M. Joers et al.

ANNALS OF NEUROLOGY (2018)

添加到收藏夹

Article Clinical Neurology

Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice

Hayley S. McLoughlin et al.

ANNALS OF NEUROLOGY (2018)

添加到收藏夹

Article Neuroimaging

Autosomal dominant cerebellar ataxias: Imaging biomarkers with high effect sizes

Isaac M. Adanyeguh et al.

NEUROIMAGE-CLINICAL (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Antisense oligonucleotide therapy for spinocerebellar ataxia type 2

Daniel R. Scoles et al.

NATURE (2017)

添加到收藏夹

Article Clinical Neurology

Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD)

Rebecca Leary et al.

NEUROPEDIATRICS (2017)

添加到收藏夹

Article Clinical Neurology

RNAi prevents and reverses phenotypes induced by mutant human ataxin-1

Megan S. Keiser et al.

ANNALS OF NEUROLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

Richard S. Finkel et al.

LANCET (2016)

添加到收藏夹

Article Medicine, Research & Experimental

Antisense Oligonucleotide Mediated Splice Correction of a Deep Intronic Mutation in OPA1

Tobias Bonifert et al.

MOLECULAR THERAPY-NUCLEIC ACIDS (2016)

添加到收藏夹

Article Clinical Neurology

NPC1 is enriched in unexplained early onset ataxia: a targeted high-throughput screening

Matthis Synofzik et al.

JOURNAL OF NEUROLOGY (2015)

添加到收藏夹

Article Clinical Neurology

Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study

Heike Jacobi et al.

LANCET NEUROLOGY (2015)

添加到收藏夹

Article Clinical Neurology

Survival and severity in dominant cerebellar ataxias

Marie-Lorraine Monin et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)

添加到收藏夹

Article Clinical Neurology

Progression of early features of spinocerebellar ataxia type 2 in individuals at risk: a longitudinal study

Luis Velazquez-Perez et al.

LANCET NEUROLOGY (2014)

添加到收藏夹

Correction Clinical Neurology

Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data (vol 12, pg 650, 2013)

H. Jacobi et al.

LANCET NEUROLOGY (2013)

添加到收藏夹

Article Clinical Neurology

A multimodal evaluation of microstructural white matter damage in spinocerebellar ataxia type 3

Rachel P. Guimaraes et al.

MOVEMENT DISORDERS (2013)

添加到收藏夹

Article Genetics & Heredity

Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study

Tetsuo Ashizawa et al.

ORPHANET JOURNAL OF RARE DISEASES (2013)

添加到收藏夹

Article Clinical Neurology

Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data

Heike Jacobi et al.

LANCET NEUROLOGY (2013)

添加到收藏夹

Article Clinical Neurology

Measuring Friedreich ataxia - Complementary features of examination and performance measures

DR Lynch et al.

NEUROLOGY (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.